| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03147040 Details | 2022-07-19 Interventional | 2 | 23 | Atezolizumab Carboplatin Breast Neoplasm… Breast Cancer | At interim analysis insufficient benefit was observed to continu the study - | |||
| NCT02933671 Details | 2022-07-19 Interventional | 4 | 11 | Ropivacaine Osteoarthritis,… Hip Osteoarthri… Pain Primary Total H… | Study halted prematurely and will not resume; participants are no longer being examined or
receiving any intervention. - | |||
| NCT02832531 Details | 2022-07-19 Interventional | 3 | 0 | Aspirin Rivaroxaban Heart Diseases Rheumatic Disea… Rheumatic Heart… | Focus on recruitment for non-inferiority trial - | |||
| NCT02325349 2014-000553-37 Details | 2022-07-19 Interventional | 2 | 1 | Radiopharmaceut… Carcinoma Carcinoma, Non-… Head and Neck N… Advanced Head a… Advanced Non-sm… | Change in protocol strategy - | |||
| NCT04796922 Details | 2022-07-18 Interventional | 3 | 0 | Obinutuzumab Rituximab Lymphoma Lymphoma, B-Cel… Lymphoma, Folli… Follicular Lymp… Marginal Zone L… | This study was withdrawn due to a business decision. - | |||
| NCT02569489 Details | 2022-07-18 Interventional | 1 | 0 | Paclitaxel Trastuzumab Breast Neoplasm… Breast Cancer | Reconsideration of Study Design; plan for alternative protocol - | |||
| NCT02201381 Details | 2022-07-18 Interventional | 3 | 0 | Atorvastatin Doxycycline Mebendazole Metformin Cancer Overall Surviva… | Prospective recruitment not possible - | |||
| NCT01773395 Details | 2022-07-18 Interventional | 2 | 123 | Busulfan Fludarabine Methotrexate Tacrolimus Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Acute Myeloid L… Chronic Myelomo… Myelodysplastic… | Recommendation by the Data and Safety Monitoring Board due to efficacy concerns - | |||
| NCT04596033 Details | 2022-07-15 Interventional | 1 | 49 | Cyclophosphamid… Fludarabine Interleukin-2 Carcinoma Carcinoma, Merk… Carcinoma, Squa… Lung Neoplasms Melanoma Small Cell Lung… Squamous Cell C… Anal Squamous C… Cutaneous Squam… Merkel Cell Car… Non-small Cell … Renal Cell Carc… Small-cell Lung… Urothelial Carc… | Business reasons - | |||
| NCT03263767 Details | 2022-07-15 Interventional | 2 | 47 | Clofarabine Cyclophosphamid… Fludarabine Thymoglobulin Graft vs Host D… Graft Versus Ho… | Security criteria (MTD) - | |||
| NCT03754140 Details | 2022-07-14 Interventional | 2 | 0 | Polidocanol Melanoma Melanoma, Cutan… Neoplasm Metast… Skin Neoplasms In-Transit Meta… | Unable to identify eligible patients within planned timeframe - | |||
| NCT01370486 Details | 2022-07-14 Interventional | 4 | 0 | Melatonin Lennox Gastaut … Syndrome Lennox-Gastaut … | The study did not received the approbation from Swissmedic. Therefore, the recruitment of
participants never started. - | |||
| NCT03365414 Details | 2022-07-13 Interventional | 3 | 0 | Pharmaceutical … Postural Orthos… Syndrome Tachycardia | Withdrawal of support of product for trial - | |||
| NCT02340221 2014-003185-25 Details | 2022-07-12 Interventional | 3 | 631 | Fulvestrant Breast Neoplasm… Recurrence Breast Cancer | The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical
benefit and limited tolerability. - | |||
| NCT05227131 2021-006387-24 Details | 2022-07-11 Interventional | 2 | 0 | Capecitabine Margetuximab Tucatinib Breast Neoplasm… Advanced Breast… HER2-positive B… Metastatic Brea… | Funder decided to not continue the study - | |||
| NCT04891718 Details | 2022-07-08 Interventional | 1 | 0 | Nivolumab Solid Tumour | Termination by pharmaceutical sponsor - | |||
| NCT02535247 Details | 2022-07-08 Interventional | 1/2 | [1 Refs] | 17 | Pembrolizumab Lymphoma Lymphoma, Non-H… Lymphoma, T-Cel… Lymphoma, T-Cel… | Merck no longer providing drug for study - | ||
| NCT05062577 Details | 2022-07-07 Interventional | 2 | 0 | ASP8062 Buprenorphine Buprenorphine, … Naloxone Opioid-Related … Substance-Relat… Opioid Use Diso… | Due to corporate strategic considerations - | |||
| NCT01555281 2010-022035-11 Details | 2022-07-07 Interventional | 1/2 | 33 | Dexamethasone Lenalidomide Nelfinavir Multiple Myelom… Neoplasms, Plas… | In connection with the restructuring of SAKK, older ongoing studies were analyzed to determine
whether a continuation of the trial would still add value to the data analysis, or whether they
do not and could therefore be prematurely terminated. - | |||
| NCT05002114 Details | 2022-07-06 Interventional | 1 | 0 | Cannabidiol Arthralgia Musculoskeletal… | there were issues with the primary study material that prohibited continuation at this time - |